Quarterly Holdings Report
for
Fidelity® Select Portfolio®
Biotechnology Portfolio
May 31, 2019
Schedule of Investments May 31, 2019 (Unaudited)
Showing Percentage of Net Assets
| Common Stocks - 98.4% | |||
| Shares | Value | ||
| Biotechnology - 88.7% | |||
| Biotechnology - 88.7% | |||
| AbbVie, Inc. | 6,390,217 | $490,193,546 | |
| Abeona Therapeutics, Inc. (a) | 75,173 | 408,941 | |
| AC Immune SA (a)(b) | 163,432 | 826,966 | |
| ACADIA Pharmaceuticals, Inc. (a) | 2,882,880 | 69,160,291 | |
| Acceleron Pharma, Inc. (a) | 1,900,241 | 75,800,613 | |
| Acorda Therapeutics, Inc. (a) | 2,235,418 | 20,767,033 | |
| Agios Pharmaceuticals, Inc. (a)(b) | 782,733 | 36,138,783 | |
| Aimmune Therapeutics, Inc. (a)(b) | 471,543 | 9,228,097 | |
| Akebia Therapeutics, Inc. (a) | 152,268 | 677,593 | |
| Albireo Pharma, Inc. (a) | 420,100 | 13,821,290 | |
| Alder Biopharmaceuticals, Inc. (a) | 546,248 | 5,910,403 | |
| Aldeyra Therapeutics, Inc. (a)(c) | 1,715,733 | 11,958,659 | |
| Alector, Inc. (b) | 674,436 | 11,404,713 | |
| Alexion Pharmaceuticals, Inc. (a) | 2,453,962 | 278,966,400 | |
| Alkermes PLC (a) | 447,174 | 9,632,128 | |
| Allakos, Inc. (a)(b) | 802,972 | 31,476,502 | |
| Allena Pharmaceuticals, Inc. (a)(c) | 29,840 | 119,062 | |
| Allena Pharmaceuticals, Inc. (c)(d) | 1,447,443 | 5,775,298 | |
| Allogene Therapeutics, Inc. (b) | 131,766 | 3,456,222 | |
| Alnylam Pharmaceuticals, Inc. (a) | 1,485,678 | 100,312,979 | |
| Amarin Corp. PLC ADR (a)(b) | 701,531 | 12,438,145 | |
| Amgen, Inc. | 2,277,122 | 379,596,237 | |
| Amicus Therapeutics, Inc. (a) | 1,902,881 | 21,445,469 | |
| AnaptysBio, Inc. (a) | 465,116 | 33,865,096 | |
| Anchiano Therapeutics Ltd. ADR | 30,900 | 157,281 | |
| Apellis Pharmaceuticals, Inc. (a) | 363,134 | 7,295,362 | |
| Applied Therapeutics, Inc. (a)(b) | 586,130 | 5,796,826 | |
| Arena Pharmaceuticals, Inc. (a) | 1,002,973 | 53,167,599 | |
| Argenx SE ADR (a) | 892,486 | 110,338,044 | |
| Array BioPharma, Inc. (a) | 4,462,510 | 117,899,514 | |
| Arrowhead Pharmaceuticals, Inc. (a)(b) | 1,254,722 | 29,749,459 | |
| Ascendis Pharma A/S sponsored ADR (a) | 649,309 | 80,942,860 | |
| Assembly Biosciences, Inc. (a) | 167,133 | 2,346,547 | |
| Atara Biotherapeutics, Inc. (a) | 965,943 | 21,453,594 | |
| aTyr Pharma, Inc. | 970,388 | 419,208 | |
| Audentes Therapeutics, Inc. (a) | 279,014 | 9,798,972 | |
| Axcella Health, Inc. | 100,000 | 1,427,000 | |
| Axcella Health, Inc. | 891,570 | 11,450,434 | |
| Bellicum Pharmaceuticals, Inc. (a) | 443,558 | 913,729 | |
| BioCryst Pharmaceuticals, Inc. (a) | 3,280,341 | 11,481,194 | |
| Biogen, Inc. (a) | 755,944 | 165,770,960 | |
| Biohaven Pharmaceutical Holding Co. Ltd. (a) | 339,090 | 19,145,021 | |
| BioMarin Pharmaceutical, Inc. (a) | 777,971 | 63,980,335 | |
| bluebird bio, Inc. (a)(b) | 437,819 | 52,503,254 | |
| Blueprint Medicines Corp. (a) | 1,475,211 | 112,116,036 | |
| Cara Therapeutics, Inc. (a)(b) | 575,786 | 11,838,160 | |
| ChemoCentryx, Inc. (a) | 1,092,532 | 12,323,761 | |
| Chimerix, Inc. (a) | 1,849,867 | 6,289,548 | |
| Clovis Oncology, Inc. (a)(b) | 499,970 | 7,389,557 | |
| Coherus BioSciences, Inc. (a)(b) | 244,587 | 4,622,694 | |
| Constellation Pharmaceuticals, Inc. (b) | 76,800 | 662,016 | |
| Corbus Pharmaceuticals Holdings, Inc. (a)(b) | 952,867 | 6,679,598 | |
| Cortexyme, Inc. (b) | 117,647 | 3,019,998 | |
| Corvus Pharmaceuticals, Inc. (a) | 607,556 | 2,290,486 | |
| Crinetics Pharmaceuticals, Inc. (a) | 990,700 | 26,035,596 | |
| CRISPR Therapeutics AG (a)(b) | 45,336 | 1,612,602 | |
| Cytokinetics, Inc. (a) | 586,090 | 6,077,753 | |
| CytomX Therapeutics, Inc. (a) | 86,181 | 832,508 | |
| CytomX Therapeutics, Inc. (a)(d) | 287,485 | 2,777,105 | |
| Denali Therapeutics, Inc. (a)(b) | 467,552 | 8,916,217 | |
| Dicerna Pharmaceuticals, Inc. (a) | 713,348 | 8,831,248 | |
| Dynavax Technologies Corp. (a)(b) | 645,798 | 3,112,746 | |
| Eagle Pharmaceuticals, Inc. (a) | 117,708 | 5,980,743 | |
| Editas Medicine, Inc. (a)(b) | 81,318 | 1,671,085 | |
| Eidos Therapeutics, Inc. (b) | 79,144 | 2,470,084 | |
| Emergent BioSolutions, Inc. (a) | 285,350 | 11,391,172 | |
| Enanta Pharmaceuticals, Inc. (a) | 161,267 | 14,589,825 | |
| Epizyme, Inc. (a) | 2,837,946 | 38,993,378 | |
| Equillium, Inc. (b) | 619,843 | 3,997,987 | |
| Esperion Therapeutics, Inc. (a)(b) | 268,384 | 12,775,078 | |
| Evelo Biosciences, Inc. (b) | 64,500 | 482,460 | |
| Exact Sciences Corp. (a) | 981,100 | 101,671,393 | |
| Exelixis, Inc. (a) | 1,203,040 | 23,567,554 | |
| Fate Therapeutics, Inc. (a) | 1,323,187 | 25,511,045 | |
| FibroGen, Inc. (a) | 1,359,619 | 49,272,593 | |
| Five Prime Therapeutics, Inc. (a) | 330,600 | 2,777,040 | |
| Forty Seven, Inc. (b) | 162,800 | 1,841,268 | |
| Galapagos Genomics NV sponsored ADR (a) | 561,734 | 63,835,452 | |
| Genmab A/S (a) | 147,983 | 25,402,859 | |
| Genomic Health, Inc. (a) | 311,339 | 16,267,463 | |
| Geron Corp. (a)(b)(c) | 15,536,850 | 22,528,433 | |
| Gilead Sciences, Inc. | 7,122,928 | 443,402,268 | |
| Global Blood Therapeutics, Inc. (a) | 1,148,043 | 69,778,054 | |
| Gossamer Bio, Inc. | 95,714 | 1,752,523 | |
| Gritstone Oncology, Inc. | 1,248,800 | 11,626,328 | |
| Halozyme Therapeutics, Inc. (a) | 2,479,707 | 36,575,678 | |
| Heron Therapeutics, Inc. (a)(b) | 2,518,445 | 42,889,118 | |
| Homology Medicines, Inc. (a) | 136,867 | 2,770,188 | |
| Immunomedics, Inc. (a)(b) | 4,365,283 | 57,054,249 | |
| Incyte Corp. (a) | 1,183,685 | 93,073,152 | |
| Insmed, Inc. (a) | 1,085,945 | 26,290,728 | |
| Intellia Therapeutics, Inc. (a)(b) | 66,132 | 917,912 | |
| Intercept Pharmaceuticals, Inc. (a)(b) | 746,925 | 61,860,329 | |
| Ionis Pharmaceuticals, Inc. (a) | 2,524,877 | 165,631,931 | |
| Iovance Biotherapeutics, Inc. (a) | 853,888 | 13,961,069 | |
| Ironwood Pharmaceuticals, Inc. Class A (a) | 3,443,420 | 37,636,581 | |
| Jounce Therapeutics, Inc. (a) | 737,774 | 3,283,094 | |
| Kaleido Biosciences, Inc. (a)(b) | 66,633 | 1,044,805 | |
| Kalvista Pharmaceuticals, Inc. (a) | 151,196 | 3,212,915 | |
| Karyopharm Therapeutics, Inc. (a)(b) | 1,102,000 | 6,215,280 | |
| Kezar Life Sciences, Inc. | 820,472 | 7,769,870 | |
| Krystal Biotech, Inc. (a)(c) | 819,996 | 25,764,274 | |
| Kura Oncology, Inc. (a) | 1,326,710 | 21,214,093 | |
| La Jolla Pharmaceutical Co. (a)(b)(c) | 1,361,589 | 7,338,965 | |
| Leap Therapeutics, Inc. (a)(b) | 840,724 | 1,219,050 | |
| Lexicon Pharmaceuticals, Inc. (a)(b) | 952,504 | 5,124,472 | |
| Ligand Pharmaceuticals, Inc. Class B (a) | 91,898 | 9,868,007 | |
| Macrogenics, Inc. (a) | 685,031 | 12,563,469 | |
| Madrigal Pharmaceuticals, Inc. (a)(b) | 34,241 | 3,163,868 | |
| MannKind Corp. (a)(b) | 1,402,861 | 1,627,319 | |
| MediciNova, Inc. (a)(b) | 96,484 | 957,121 | |
| Minerva Neurosciences, Inc. (a)(c) | 2,218,614 | 11,558,979 | |
| Miragen Therapeutics, Inc. (a)(b)(c) | 2,888,656 | 6,846,115 | |
| Mirati Therapeutics, Inc. (a)(b) | 735,201 | 49,839,276 | |
| Moderna, Inc. (b) | 1,400 | 29,092 | |
| Moderna, Inc. | 2,189,172 | 45,036,084 | |
| Momenta Pharmaceuticals, Inc. (a) | 1,315,656 | 15,301,079 | |
| Morphosys AG (a) | 141,175 | 13,634,345 | |
| Morphosys AG sponsored ADR (a) | 1,114,727 | 26,764,595 | |
| Natera, Inc. (a) | 798,331 | 18,281,780 | |
| Neon Therapeutics, Inc. | 407,398 | 1,988,102 | |
| Neurocrine Biosciences, Inc. (a) | 1,749,051 | 148,284,544 | |
| Oragenics, Inc. (a) | 155,806 | 72,481 | |
| Pharming Group NV (a)(b) | 19,512,456 | 16,300,799 | |
| Portola Pharmaceuticals, Inc. (a)(b) | 477,303 | 13,311,981 | |
| Principia Biopharma, Inc. | 725,627 | 21,231,846 | |
| ProQR Therapeutics BV (a)(b) | 908,886 | 11,024,787 | |
| Protagonist Therapeutics, Inc. (a) | 608,963 | 6,126,168 | |
| Prothena Corp. PLC (a) | 769,935 | 7,175,794 | |
| PTC Therapeutics, Inc. (a) | 2,242,247 | 89,914,105 | |
| Puma Biotechnology, Inc. (a) | 298,968 | 4,421,737 | |
| Ra Pharmaceuticals, Inc. (a) | 466,834 | 10,097,619 | |
| Radius Health, Inc. (a)(b) | 794,921 | 16,526,408 | |
| Regeneron Pharmaceuticals, Inc. (a) | 214,365 | 64,678,208 | |
| REGENXBIO, Inc. (a) | 459,408 | 19,763,732 | |
| Repligen Corp. (a) | 342,486 | 23,792,502 | |
| Replimune Group, Inc. (a) | 428,010 | 5,786,695 | |
| Retrophin, Inc. (a) | 1,153,799 | 21,379,895 | |
| Rigel Pharmaceuticals, Inc. (a) | 904,339 | 1,926,242 | |
| Rocket Pharmaceuticals, Inc. (a)(b) | 1,464,787 | 23,919,972 | |
| Rubius Therapeutics, Inc. | 58,900 | 851,694 | |
| Sage Therapeutics, Inc. (a) | 844,793 | 145,194,573 | |
| Sangamo Therapeutics, Inc. (a) | 2,744,621 | 24,015,434 | |
| Sarepta Therapeutics, Inc. (a) | 1,120,005 | 127,512,569 | |
| Scholar Rock Holding Corp. (c) | 1,506,547 | 27,630,072 | |
| Seattle Genetics, Inc. (a) | 615,990 | 40,082,469 | |
| Selecta Biosciences, Inc. (a)(b) | 512,660 | 1,020,193 | |
| Seres Therapeutics, Inc. (a)(b) | 1,633,975 | 5,571,855 | |
| Sienna Biopharmaceuticals, Inc. (a) | 265,714 | 310,885 | |
| Solid Biosciences, Inc. (a)(b) | 317,997 | 1,758,523 | |
| Spectrum Pharmaceuticals, Inc. (a) | 2,061,703 | 15,174,134 | |
| Stemline Therapeutics, Inc. (a) | 737,698 | 9,685,975 | |
| Surface Oncology, Inc. (a) | 44,796 | 163,505 | |
| Synthorx, Inc. (b) | 350,362 | 5,027,695 | |
| Syros Pharmaceuticals, Inc. (a) | 704,361 | 4,155,730 | |
| Syros Pharmaceuticals, Inc. (a)(d) | 303,621 | 1,791,364 | |
| Syros Pharmaceuticals, Inc. warrants 10/10/22 (a)(e) | 21,625 | 32,438 | |
| TG Therapeutics, Inc. (a)(b) | 2,027,037 | 12,709,522 | |
| Translate Bio, Inc. (b) | 508,351 | 5,327,518 | |
| Translate Bio, Inc. (d) | 1,014,146 | 10,628,250 | |
| Twist Bioscience Corp. | 970,140 | 25,039,313 | |
| Ultragenyx Pharmaceutical, Inc. (a) | 1,062,037 | 58,337,692 | |
| uniQure B.V. (a) | 296,462 | 17,583,161 | |
| United Therapeutics Corp. (a) | 59,725 | 5,015,108 | |
| UNITY Biotechnology, Inc. | 51,400 | 419,424 | |
| Vanda Pharmaceuticals, Inc. (a) | 566,592 | 8,317,571 | |
| Verastem, Inc. (a)(b) | 2,671,779 | 3,526,748 | |
| Vertex Pharmaceuticals, Inc. (a) | 1,680,452 | 279,257,513 | |
| Viking Therapeutics, Inc. (a)(b) | 637,500 | 4,902,375 | |
| Voyager Therapeutics, Inc. (a) | 559,529 | 12,203,327 | |
| X4 Pharmaceuticals, Inc. (a)(b)(c) | 900,000 | 13,833,000 | |
| X4 Pharmaceuticals, Inc. warrants 4/12/24 (a) | 450,000 | 3,390,322 | |
| Xencor, Inc. (a) | 1,349,543 | 41,619,906 | |
| Y-mAbs Therapeutics, Inc. | 1,265,742 | 25,783,165 | |
| Zafgen, Inc. (a) | 901,146 | 1,649,097 | |
| Zealand Pharma A/S (a) | 205,144 | 4,213,543 | |
| Zymeworks, Inc. (a) | 603,095 | 11,464,836 | |
| 5,865,674,371 | |||
| Capital Markets - 0.1% | |||
| Asset Management & Custody Banks - 0.1% | |||
| Arix Bioscience PLC (a)(d) | 2,049,700 | 3,861,086 | |
| Health Care Equipment & Supplies - 0.7% | |||
| Health Care Equipment - 0.7% | |||
| Novocure Ltd. (a) | 151,089 | 8,025,848 | |
| Novocure Ltd. (a)(d) | 701,713 | 37,274,995 | |
| 45,300,843 | |||
| Health Care Providers & Services - 0.3% | |||
| Health Care Services - 0.3% | |||
| G1 Therapeutics, Inc. (a) | 789,800 | 16,554,208 | |
| OptiNose, Inc. (a) | 162,115 | 1,230,453 | |
| Precipio, Inc. (a)(f) | 525 | 2,861 | |
| 17,787,522 | |||
| Life Sciences Tools & Services - 0.1% | |||
| Life Sciences Tools & Services - 0.1% | |||
| Evotec OAI AG (a) | 159,200 | 3,850,459 | |
| Personal Products - 0.0% | |||
| Personal Products - 0.0% | |||
| MYOS Corp. (a) | 33,334 | 40,001 | |
| Pharmaceuticals - 8.5% | |||
| Pharmaceuticals - 8.5% | |||
| Adimab LLC (a)(e)(f)(g) | 1,954,526 | 87,210,950 | |
| Aerie Pharmaceuticals, Inc. (a) | 533,125 | 19,416,413 | |
| Afferent Pharmaceuticals, Inc. rights 12/31/24 (a)(e) | 8,274,568 | 12,329,106 | |
| Aradigm Corp. (a) | 148,009 | 29,602 | |
| Aradigm Corp. (a) | 11,945 | 2,389 | |
| Arvinas Holding Co. LLC (a) | 611,000 | 12,782,120 | |
| BioXcel Therapeutics, Inc. (a) | 706,789 | 7,555,574 | |
| Chiasma, Inc. (a) | 1,553,299 | 11,028,423 | |
| Chiasma, Inc. warrants 12/16/24 (a) | 382,683 | 1,097,727 | |
| Corcept Therapeutics, Inc. (a)(b) | 764,795 | 7,479,695 | |
| Cyclerion Therapeutics, Inc. (a) | 436,725 | 6,092,314 | |
| Cyclerion Therapeutics, Inc. (f) | 94,809 | 1,322,586 | |
| Dermira, Inc. (a)(b) | 241,622 | 2,256,749 | |
| Dova Pharmaceuticals, Inc. (a)(b) | 1,028,720 | 9,073,310 | |
| GW Pharmaceuticals PLC ADR (a)(b) | 28,600 | 4,954,664 | |
| Hookipa Pharma, Inc. | 300,000 | 2,574,000 | |
| Horizon Pharma PLC (a) | 1,091,319 | 26,006,132 | |
| Idorsia Ltd. (a)(b) | 432,921 | 9,642,086 | |
| InflaRx NV (a) | 250,500 | 9,015,495 | |
| Intra-Cellular Therapies, Inc. (a) | 544,748 | 7,076,277 | |
| Melinta Therapeutics, Inc. (a)(b) | 145,068 | 308,995 | |
| Milestone Pharmaceuticals, Inc. | 239,600 | 4,959,720 | |
| MyoKardia, Inc. (a) | 1,059,701 | 49,360,873 | |
| Nektar Therapeutics (a) | 576,951 | 18,070,105 | |
| NeurogesX, Inc. (a)(e) | 2,550,000 | 26 | |
| NGM Biopharmaceuticals, Inc. | 288,200 | 4,075,148 | |
| ObsEva SA (a) | 1,373,362 | 17,318,095 | |
| Ocular Therapeutix, Inc. (a)(b) | 678,920 | 1,968,868 | |
| Odonate Therapeutics, Inc. (a)(b) | 305,194 | 6,558,619 | |
| Reata Pharmaceuticals, Inc. (a) | 51,297 | 4,374,095 | |
| RedHill Biopharma Ltd. sponsored ADR (a) | 93,300 | 691,353 | |
| resTORbio, Inc. (a) | 307,512 | 2,217,162 | |
| Rhythm Pharmaceuticals, Inc. (a) | 660,818 | 16,646,005 | |
| RPI International Holdings LP (a)(e)(f) | 54,958 | 8,387,690 | |
| Spero Therapeutics, Inc. (a) | 240,752 | 2,710,868 | |
| Stemcentrx, Inc. rights 12/31/21 (a)(e) | 876,163 | 1,068,919 | |
| Sutro Biopharma, Inc. (a) | 400,000 | 4,580,000 | |
| The Medicines Company (a)(b) | 977,308 | 34,841,030 | |
| TherapeuticsMD, Inc. (a)(b) | 3,510,042 | 10,740,729 | |
| Theravance Biopharma, Inc. (a) | 354,600 | 5,893,452 | |
| Trevi Therapeutics, Inc. | 792,700 | 7,919,073 | |
| Tricida, Inc. | 819,265 | 30,099,796 | |
| Turning Point Therapeutics, Inc. (b) | 239,629 | 8,343,882 | |
| UroGen Pharma Ltd. (a)(b) | 588,203 | 20,034,194 | |
| Urovant Sciences Ltd. (a)(b)(c) | 1,710,836 | 13,173,437 | |
| Verrica Pharmaceuticals, Inc. (a)(b) | 621,800 | 4,433,434 | |
| WAVE Life Sciences (a)(b) | 322,412 | 7,392,907 | |
| Xeris Pharmaceuticals, Inc. | 387,931 | 4,255,603 | |
| Zogenix, Inc. (a) | 970,021 | 36,560,091 | |
| 563,929,781 | |||
| TOTAL COMMON STOCKS | |||
| (Cost $4,896,091,547) | 6,500,444,063 | ||
| Preferred Stocks - 0.7% | |||
| Convertible Preferred Stocks - 0.6% | |||
| Biotechnology - 0.4% | |||
| Biotechnology - 0.4% | |||
| 23andMe, Inc. Series E (a)(e)(f) | 1,505,457 | 18,652,612 | |
| Immunocore Ltd. Series A (a)(e)(f) | 73,318 | 9,024,520 | |
| 27,677,132 | |||
| Health Care Technology - 0.2% | |||
| Health Care Technology - 0.2% | |||
| Codiak Biosciences, Inc.: | |||
| Series A 8.00% (a)(e)(f) | 856,366 | 3,108,609 | |
| Series B 8.00% (a)(e)(f) | 2,783,187 | 10,102,969 | |
| 13,211,578 | |||
| Pharmaceuticals - 0.0% | |||
| Pharmaceuticals - 0.0% | |||
| Afferent Pharmaceuticals, Inc. Series C (a)(e)(f) | 8,274,568 | 83 | |
| TOTAL CONVERTIBLE PREFERRED STOCKS | 40,888,793 | ||
| Nonconvertible Preferred Stocks - 0.1% | |||
| Biotechnology - 0.1% | |||
| Biotechnology - 0.1% | |||
| Yumanity Holdings LLC Class A (a)(e)(f) | 588,700 | 3,879,533 | |
| TOTAL PREFERRED STOCKS | |||
| (Cost $43,281,686) | 44,768,326 | ||
| Money Market Funds - 7.9% | |||
| Fidelity Cash Central Fund 2.41% (h) | 49,730,029 | 49,739,975 | |
| Fidelity Securities Lending Cash Central Fund 2.42% (h)(i) | 474,696,804 | 474,744,274 | |
| TOTAL MONEY MARKET FUNDS | |||
| (Cost $524,446,472) | 524,484,249 | ||
| TOTAL INVESTMENT IN SECURITIES - 107.0% | |||
| (Cost $5,463,819,705) | 7,069,696,638 | ||
| NET OTHER ASSETS (LIABILITIES) - (7.0)% | (459,945,330) | ||
| NET ASSETS - 100% | $6,609,751,308 |
Legend
(a) Non-income producing
(b) Security or a portion of the security is on loan at period end.
(c) Affiliated company
(d) Security exempt from registration under Rule 144A of the Securities Act of 1933. These securities may be resold in transactions exempt from registration, normally to qualified institutional buyers. At the end of the period, the value of these securities amounted to $62,108,098 or 0.9% of net assets.
(e) Level 3 security
(f) Restricted securities - Investment in securities not registered under the Securities Act of 1933 (excluding 144A issues). At the end of the period, the value of restricted securities (excluding 144A issues) amounted to $141,692,413 or 2.1% of net assets.
(g) Investment is owned by a wholly-owned subsidiary (Subsidiary) that is treated as a corporation for U.S. tax purposes.
(h) Affiliated fund that is generally available only to investment companies and other accounts managed by Fidelity Investments. The rate quoted is the annualized seven-day yield of the fund at period end. A complete unaudited listing of the fund's holdings as of its most recent quarter end is available upon request. In addition, each Fidelity Central Fund's financial statements are available on the SEC's website or upon request.
(i) Investment made with cash collateral received from securities on loan.
Additional information on each restricted holding is as follows:
| Security | Acquisition Date | Acquisition Cost |
| 23andMe, Inc. Series E | 6/18/15 | $16,299,991 |
| Adimab LLC | 9/17/14 - 6/5/15 | $31,814,048 |
| Afferent Pharmaceuticals, Inc. Series C | 7/1/15 | $0 |
| Codiak Biosciences, Inc. Series A 8.00% | 11/12/15 | $856,366 |
| Codiak Biosciences, Inc. Series B 8.00% | 11/12/15 | $8,349,561 |
| Cyclerion Therapeutics, Inc. | 4/2/19 | $1,404,026 |
| Immunocore Ltd. Series A | 7/27/15 | $13,796,921 |
| Precipio, Inc. | 2/3/12 | $2,828,200 |
| RPI International Holdings LP | 5/21/15 | $6,479,548 |
| Yumanity Holdings LLC Class A | 2/8/16 | $3,978,847 |
Affiliated Central Funds
Information regarding fiscal year to date income earned by the Fund from investments in Fidelity Central Funds is as follows:
| Fund | Income earned |
| Fidelity Cash Central Fund | $488,861 |
| Fidelity Securities Lending Cash Central Fund | 807,583 |
| Total | $1,296,444 |
Amounts in the income column in the above table include any capital gain distributions from underlying funds.
Other Affiliated Issuers
An affiliated company is a company in which the Fund has ownership of at least 5% of the voting securities. Fiscal year to date transactions with companies which are or were affiliates are as follows:
| Affiliate | Value, beginning of period | Purchases | Sales Proceeds | Dividend Income | Realized Gain (loss) | Change in Unrealized appreciation (depreciation) | Value, end of period |
| Aldeyra Therapeutics, Inc. | $15,316,715 | $-- | $1,427,194 | $-- | $(1,046,431) | $(884,431) | $11,958,659 |
| Allena Pharmaceuticals, Inc. | 302,085 | -- | 69,877 | -- | (98,123) | (15,023) | 119,062 |
| Allena Pharmaceuticals, Inc. | 10,450,538 | -- | -- | -- | -- | (4,675,240) | 5,775,298 |
| BioXcel Therapeutics, Inc. | 7,133,758 | -- | 1,390,434 | -- | (88,583) | 1,900,833 | -- |
| Chiasma, Inc. | 6,554,922 | -- | -- | -- | -- | 4,473,501 | -- |
| Geron Corp. | 22,683,801 | -- | -- | -- | -- | (155,368) | 22,528,433 |
| Krystal Biotech, Inc. | 27,623,544 | -- | 13,662,105 | -- | 6,508,065 | 5,294,770 | 25,764,274 |
| Kura Oncology, Inc. | 29,861,469 | -- | 9,417,571 | -- | (2,521,237) | 3,291,432 | -- |
| La Jolla Pharmaceutical Co. | 6,781,849 | 1,074,435 | -- | -- | -- | (517,319) | 7,338,965 |
| Minerva Neurosciences, Inc. | 22,014,584 | -- | 4,203,736 | -- | (818,315) | (5,433,554) | 11,558,979 |
| Miragen Therapeutics, Inc. | 8,088,237 | -- | -- | -- | -- | (1,242,122) | 6,846,115 |
| Scholar Rock Holding Corp. | 28,051,905 | -- | -- | -- | -- | (421,833) | 27,630,072 |
| Seres Therapeutics, Inc. | 14,224,512 | -- | 4,512,085 | -- | (23,135,722) | 18,995,150 | -- |
| Urovant Sciences Ltd. | 16,285,606 | 4,174,942 | -- | -- | -- | (7,287,111) | 13,173,437 |
| X4 Pharmaceuticals, Inc. | -- | 9,900,000 | -- | -- | -- | 3,933,000 | 13,833,000 |
| Total | $215,373,525 | $15,149,377 | $34,683,002 | $-- | $(21,200,346) | $17,256,685 | $146,526,294 |
Investment Valuation
Investments are valued as of 4:00 p.m. Eastern time on the last calendar day of the period. Security transactions are accounted for as of trade date. The Board of Trustees (the Board) has delegated the day to day responsibility for the valuation of the Fund's investments to the Fair Value Committee (the Committee) established by the Fund's investment adviser. In accordance with valuation policies and procedures approved by the Board, the Fund attempts to obtain prices from one or more third party pricing vendors or brokers to value its investments. When current market prices, quotations or currency exchange rates are not readily available or reliable, investments will be fair valued in good faith by the Committee, in accordance with procedures adopted by the Board. Factors used in determining fair value vary by investment type and may include market or investment specific events. The frequency with which these procedures are used cannot be predicted and they may be utilized to a significant extent. The Committee oversees the Fund’s valuation policies and procedures and reports to the Board on the Committee's activities and fair value determinations. The Board monitors the appropriateness of the procedures used in valuing the Fund's investments and ratifies the fair value determinations of the Committee. The Fund categorizes the inputs to valuation techniques used to value its investments into a disclosure hierarchy consisting of three levels: Level 1 - quoted prices in active markets for identical investments: Level 2 - other significant observable inputs (including quoted prices for similar investments, interest rates, prepayment speeds etc.): Level 3 - unobservable inputs (including the Fund's own assumptions based on the best information available). Changes in valuation techniques may result in transfers in or out of an assigned level within the disclosure hierarchy. Valuation techniques used to value the Fund's investments by major category are as follows:
Equity securities, including restricted securities, for which market quotations are readily available, are valued at the last reported sale price or official closing price as reported by a third party pricing vendor on the primary market or exchange on which they are traded and are categorized as Level 1 in the hierarchy. In the event there were no sales during the day or closing prices are not available, securities are valued at the last quoted bid price or may be valued using the last available price and are generally categorized as Level 2 in the hierarchy. For foreign equity securities, when market or security specific events arise, comparisons to the valuation of American Depositary Receipts (ADRs), futures contracts, Exchange-Traded Funds (ETFs) and certain indexes as well as quoted prices for similar securities may be used and would be categorized as Level 2 in the hierarchy. For equity securities, including restricted securities, where observable inputs are limited, assumptions about market activity and risk are used and these securities may be categorized as Level 3 in the hierarchy. Equity securities, including restricted securities, for which observable inputs are not available, are valued using alternate valuation approaches, including the market approach and the income approach and are categorized as Level 3 in the hierarchy. The market approach generally consists of using comparable market transactions while the income approach generally consists of using the net present value of estimated future cash flows, adjusted as appropriate for liquidity, credit, market and/or other risk factors.
Investments in open-end mutual funds, including the Fidelity Central Funds, are valued at their closing net asset value each business day and are categorized as Level 1 in the hierarchy.
For additional information on the Fund's significant accounting policies, please refer to the Fund's most recent semiannual or annual shareholder report.
The fund's schedule of investments as of the date on the cover of this report has not been audited. This report is provided for the general information of the fund's shareholders. For more information regarding the fund and its holdings, please see the fund's most recent prospectus and annual report.
Third party trademarks and service marks are the property of their respective owners. All other trademarks and service marks are the property of FMR LLC or an affiliate.